What the End of GLP-1 Compounding Means for You

For about two years, the cheapest way onto a GLP-1 was a compounded vial, and the reason was a single word: shortage. That era has ended. Once the FDA declared the semaglutide and tirzepatide shortages resolved, the legal basis for mass-compounding those two molecules went away — and with it, a large slice of the low-cost telehealth market you may have been shopping. This is a plain-English explainer of what changed, who can still get compounded product, and who now has to move to a brand-name drug.

Why compounding was allowed in the first place

Compounded semaglutide and tirzepatide were never FDA-approved. They were allowed to fill a gap. When a drug is on the FDA's shortage list, compounding pharmacies get room to prepare their own versions so patients are not left without treatment. Two lanes did this work: **503A pharmacies**, which compound for an individual patient against a prescription, and **503B outsourcing facilities**, which are FDA-registered, inspected to manufacturing standards, and can compound in larger batches². Neither lane produces an FDA-approved drug, but during the shortage both were permitted to supply GLP-1s — and an entire market of flat-priced, compounded-only telehealth brands grew up around that permission.

The molecule itself was rarely the issue. Compounded programs used real semaglutide, the same drug that produced roughly 15% mean weight loss in the STEP-1 trial⁴, and real tirzepatide, which reached about 21% at its top dose in SURMOUNT-1⁵. What the shortage created was not a different drug — it was a temporary legal doorway. That doorway is what closed.

The wind-down, by the dates

The shortages resolved on separate tracks, and the enforcement deadlines that followed are the dates that actually reshaped access.

**Tirzepatide went first.** The FDA determined the tirzepatide shortage resolved in late 2024. Compounders got a short runway to stop: state-licensed 503A pharmacies had until roughly mid-February 2025, and 503B outsourcing facilities until roughly mid-March 2025, before the agency's enforcement discretion ended¹.

**Semaglutide followed.** The FDA removed semaglutide injection products from the shortage list on February 21, 2025³. Its runway ran a couple of months longer: 503A pharmacies had until roughly late April 2025, and 503B facilities until roughly late May 2025, to wind down¹.

By mid-2025, in other words, the days of buying a straight compounded copy of Wegovy or Zepbound simply because it was cheaper were effectively over. The FDA has since moved to make that permanent, proposing in 2026 to strike semaglutide and tirzepatide from the list of bulk substances 503B facilities may compound from at all¹. Treat the compounded-copy market as closing, not paused.

Who can *still* get compounded GLP-1

"Compounding is banned" is the headline, and it is wrong. Compounding these molecules is restricted, not outlawed. The key rule is that a pharmacy may not compound a drug that is "essentially a copy" of a commercially available, FDA-approved product². Once Wegovy and Zepbound are available, a plain compounded duplicate of them is exactly that kind of copy — which is what the shortage exception used to excuse.

There is a narrow, legitimate lane that survives. A 503A pharmacy may still compound a semaglutide or tirzepatide preparation for a specific patient when a prescriber documents that a change from the approved drug produces a **significant clinical difference** for that person². In practice that can mean a documented allergy or intolerance to an inactive ingredient in the approved product, or a medically necessary dose or formulation the approved product does not offer. This is a clinical judgment made for one patient — not a marketing category, and not a workaround for "I want it cheaper." If a provider is offering "personalized" or combination GLP-1 formulations to essentially everyone who signs up, treat that as a compliance question, not a feature.

Who now has to move to brand-name

If your reason for choosing compounded was price and availability — the reason most people had — you are in the group that has to transition. Straightforward, cost-driven compounded copies are the exact use the wind-down removed. The realistic paths forward are brand-name Wegovy (semaglutide) or Zepbound (tirzepatide), an FDA-approved alternative your clinician recommends, or, only if you genuinely qualify, the narrow clinical-difference lane above.

The good news is that the price gap narrowed while this played out. Facing an end to compounded competition, the brand manufacturers rolled out cash-pay channels for people without coverage, which softened the sticker shock of switching, even if brand-name still generally costs more out of pocket than compounded did. We keep the current numbers in what compounded GLP-1 costs per month and weigh the whole trade in compounded vs brand-name GLP-1.

If you are being switched, don't let the gap open

The medical risk in this transition is not the switch itself — it is an interruption. Semaglutide and tirzepatide are maintenance drugs, and stopping tends to reverse the result. In STEP-4, people who came off semaglutide regained weight over the following months, while those who continued kept losing⁶. SURMOUNT-4 showed the same pattern for tirzepatide: withdrawal led to substantial regain, continuation to further loss⁷. So if your compounded program is ending, the goal is a continuous handoff to an approved product — not a two-month gap while you shop. Line up the next prescription before the current supply runs out, and talk to a clinician about dose continuity.

How this reshapes which provider you pick

The wind-down quietly re-sorted the field, and the old scoreboard is out of date. A provider that was compounded-only on price now has to prove it can actually keep you on treatment. The questions that matter most now:

- **Can it prescribe brand-name?** Access to Wegovy and Zepbound — and help navigating cash-pay or coverage — is the new baseline, not a luxury. - **Is its formulary broad enough to pivot?** A provider that can move you between molecules and between compounded (where you legitimately qualify) and brand-name on one account beats one that forces a re-signup. - **Is its "personalized compound" claim defensible?** Blanket personalized-formulation marketing after the wind-down is a flag to scrutinize, not a reassurance. - **Is it honest about all of the above?** Price honesty and verification still carry the most weight, because a clean transition depends on both.

That is the lens our Verdict Score methodology now applies to every provider, and it is why the ranked reviews are the place to start rather than a search bar. If you are choosing fresh, run the full how to choose a GLP-1 telehealth provider checklist — the verification and pharmacy questions in it matter more, not less, now that the easy compounded route is gone.

This is editorial information, not medical advice. Do not stop, start, or switch a GLP-1 medication without talking to a licensed clinician.